Takeda Pharmaceutical Company Limited (4502.T)
| Previous close | 4,138.00 |
| Open | 4,140.00 |
| Bid | 4,142.00 x 0 |
| Ask | 4,145.00 x 0 |
| Day's range | 4,126.00 - 4,159.00 |
| 52-week range | 3,900.00 - 4,873.00 |
| Volume | |
| Avg. volume | 3,923,685 |
| Market cap | 6.499T |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | 45.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 196.00 (4.73%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
OSAKA, Japan & CAMBRIDGE, Mass., June 14, 2024--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commerc
- Business Wire
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
CAMBRIDGE, Mass., June 11, 2024--Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its partnership with Partners In Health (PIH), an international nonprofit organization, to support a new initiative with PIH that aims to address social determinants of health and improve access to care within communities across Massachusetts. This builds on Takeda’s existing global partnership with PIH that has been in place since 2017.
- Business Wire
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2024--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall dis
